SCHEMBL3339779

SCHEMBL3339779

O=C(NNc1nc(-c2ccc(Br)cc2)cs1)c1cccnc1

nearest known ligand 0.79

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 8/20 0.79
ALDH1A1 P00352 7/20 0.79
MEN1 O00255 8/20 0.70
KMT2A Q03164 8/20 0.70
CYP1A2 P05177 1/20 0.70
CYP2C19 P33261 1/20 0.70
MAPT P10636 10/20 0.63
GAA P10253 8/20 0.63
KDM4E B2RXH2 7/20 0.63
SMN1; SMN2 Q16637 6/20 0.63
HTT P42858 5/20 0.63
MAPK1 P28482 3/20 0.62
RAB9A P51151 1/20 0.61
TDP1 Q9NUW8 3/20 0.60
ABL1 P00519 1/20 0.56
CYP19A1 P11511 1/20 0.51
MAOA P21397 1/20 0.51
MAOB P27338 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3337873 0.90 MAPT (0.79) LMNAALDH1A1MEN1KMT2AMAPT
SCHEMBL5698578 0.88 LMNA (1.00) LMNAALDH1A1MEN1KMT2ACYP1A2
SCHEMBL3338658 0.86 MAPT (0.71) LMNAALDH1A1MEN1KMT2ACYP1A2
SCHEMBL3344402 0.85 MAPT (0.66) LMNAALDH1A1MEN1KMT2ACYP1A2
SCHEMBL3337838 0.83 LMNA (0.56) LMNAALDH1A1MEN1KMT2ACYP1A2
SCHEMBL3341958 0.82 MAPT (0.79) LMNAALDH1A1MEN1KMT2AMAPT
SCHEMBL3343782 0.80 MAPT (0.78) LMNAALDH1A1MEN1KMT2AMAPT
SCHEMBL12249057 0.80 LMNA (0.82) LMNAALDH1A1MEN1KMT2ACYP1A2
SCHEMBL3344076 0.80 MAPT (0.66) LMNAALDH1A1MEN1KMT2AMAPT
SCHEMBL11469127 0.77 LMNA (1.00) LMNAALDH1A1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US claimed
US-8410152-B2 Thiazolhydrazides for treatment of neurodegenerative diseases MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) 2013-04-02 US disclosed
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES HTT, MAPT, SNCA LMNA 2315/4885ALDH1A1 728/4885MEN1 1886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.